Voiculescu Mihai, Nanau Radu M, Neuman Manuela G
Division of Nephrology and Internal Medicine, Fundeni Clinical Institute and Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, Ontario, Canada.
J Gastrointestin Liver Dis. 2014 Dec;23(4):425-9. doi: 10.15403/jgld.2014.1121.234.bna.
Non-alcoholic fatty liver disease (NAFLD) is by far the most common form of chronic liver disease worldwide, affecting adults as well as children. Under the term of NAFLD there is a wide spectrum of diseases ranging from simple steatosis to the non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC). Several mechanisms have been described to influence the progression of the disease from the benign NAFL to the aggressive NASH. The imbalance between pro- and anti-oxidant mechanisms and between pro- and anti-inflammatory cytokines is thought to play a pivotal role in the pathogenesis of NAFLD and disease progression toward NASH and fibrosis. The present review intends to look at some of the mechanistic biomarkers to be employed in establishing an early diagnosis in HCC derived from NASH.
非酒精性脂肪性肝病(NAFLD)是目前全球最常见的慢性肝病形式,影响成人和儿童。在NAFLD这一术语下,有一系列广泛的疾病,从单纯性脂肪变性到非酒精性脂肪性肝炎(NASH),后者可进展为肝硬化和肝细胞癌(HCC)。已经描述了几种机制来影响疾病从良性NAFL向侵袭性NASH的进展。促氧化与抗氧化机制之间以及促炎与抗炎细胞因子之间的失衡被认为在NAFLD的发病机制以及疾病向NASH和纤维化进展中起关键作用。本综述旨在探讨一些用于在源自NASH的HCC中进行早期诊断的机制性生物标志物。